Actively Recruiting
Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
Led by University Hospital, Clermont-Ferrand · Updated on 2026-02-23
90
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are exploring whether specific molecules in the blood called microRNAs are linked to how often and how severely people develop nerve damage from chemotherapy. This study focuses on patients receiving cancer drugs known to affect the nerves, including paclitaxel for lung cancer and oxaliplatin for colorectal cancer. The goal is to better understand the relationship between these molecules and chemotherapy-induced peripheral neuropathy. Participants will be grouped based on their cancer type and treatment: one group with lung cancer treated with paclitaxel, and another with colorectal cancer treated with oxaliplatin. The study involves assessing blood levels of microRNAs and neurofilament light chain, along with evaluating the grade and severity of sensory and motor chemotherapy-induced peripheral neuropathy and pain at specific time points: day 1, day 43, and day 155. During the study, participants will undergo blood tests and assessments of neuropathy severity and pain at the three scheduled visits. Researchers will measure the concentration of microRNAs and other biomarkers in the blood and monitor the occurrence and severity of neuropathic pain. This monitoring will help understand the progression and impact of chemotherapy-induced nerve damage over the study period, which lasts about five months.
CONDITIONS
Brief Title
Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles
- Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles
- Age 18 years or older
You will not qualify if you...
- Neurodegenerative disease such as Parkinson's or Alzheimer's
- History of stroke
- Pre-existing neuropathy with sensory score 15 or higher on QLQ-CIPN20
- Pain score 4 or higher on NRS
- Pregnant or breastfeeding women
- Patients under guardianship, curatorship, deprived of liberty, or under legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 5 months
Participants undergo assessments including blood tests and pain evaluations to monitor chemotherapy-induced peripheral neuropathy.
3 visits (day 1, day 43, and day 155)
Trial Site Locations
Total: 1 location
1
CHU Clermont-Ferrand
Clermont-Ferrand, France
Actively Recruiting
Research Team
L
Lise Laclautre
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here